SCHEMBL7095047

SCHEMBL7095047

O=C(NCc1ccc(F)cc1)N1CCC(Br)CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.67
TSHR P16473 1/20 0.67
SMN1; SMN2 Q16637 2/20 0.62
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
TP53 P04637 1/20 0.56
NPC1 O15118 1/20 0.55
NPSR1 Q6W5P4 1/20 0.53
PKM P14618 1/20 0.53
TUBB4A P04350 1/20 0.51
TUBB P07437 1/20 0.51
TUBA3C P0DPH7 1/20 0.51
TUBA1B P68363 1/20 0.51
TUBA4A P68366 1/20 0.51
TUBB4B P68371 1/20 0.51
TUBB3 Q13509 1/20 0.51
TUBB2A Q13885 1/20 0.51
TUBB8 Q3ZCM7 1/20 0.51
TUBA3E Q6PEY2 1/20 0.51
TUBA1A Q71U36 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7095416 0.87 ALDH1A1 (0.68) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A
SCHEMBL4559263 0.83 TP53 (0.63) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A
SCHEMBL13873489 0.82 ALDH1A1 (0.62) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A
SCHEMBL4670795 0.79 TP53 (0.59) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A
SCHEMBL5474021 0.79 MEN1 (0.76) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A
SCHEMBL5956394 0.79 TP53 (0.59) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A
Hydrochloric Acid SCHEMBL28550900 0.78 TP53 (0.58) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A
Hydrochloric Acid SCHEMBL12466676 0.78 MEN1 (0.65) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A
SCHEMBL13873498 0.78 EPHX2 (0.64) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A
SCHEMBL12466477 0.77 SMN1; SMN2 (0.79) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6605618-B2 Antidiabetic agents; hypoglycemic agents; anticholesterol agents; side effect reduction WYETH 2003-08-12 US disclosed
US-20030018045-A1 Heterocyclic beta-3 adrenergic receptor agonists WYETH (US) 2003-01-23 US disclosed
US-6451814-B1 SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION WYETH 2002-09-17 US disclosed
US-20020028832-A1 Heterocyclic beta-3 adrenergic receptor agonists AMERICAN HOME PRODUCTS CORPORATION (US) 2002-03-07 US disclosed
WO-2002006229-A2 HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS WYETH (US) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018045-A1 Heterocyclic beta-3 adrenergic receptor agonists ADRB2, ADRB1, ADRB3 ALDH1A1 725/4885TSHR 603/4885SMN1; SMN2 3162/4885
US-20020028832-A1 Heterocyclic beta-3 adrenergic receptor agonists ADRB1, ADRB3, ADRB2 ALDH1A1 524/4885TSHR 552/4885SMN1; SMN2 2712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.